论文部分内容阅读
本文报道了两个新头孢菌素:氧哌羟苯唑头孢菌素(Cefoporazone,CPZ,T1551)和噻乙胺唑头孢菌素(Cefotiam,CTM,SCE963)与其它临床运用的头孢菌素类药物的体外抗菌活性比较。试验采用琼脂平板稀释法,受试菌株均采用较低的接种量(10~3菌落形成单位,cfu/ml)。对24株大肠杆菌,CTM和CPZ的活性均高于噻吩甲氧头孢菌素(Cefoxitin)、头孢菌素Ⅴ(Cefazolin)和呋肟头孢菌素(Cefuroxime);其中CTM活性最高。受试的肺炎克氏杆菌菌株均对CTM很敏感;但仅有20～25%菌株对浓度为0.12～0.25mg/l的CPZ敏感,其余的需≥4mg/l才呈现抑制,CPZ在这点上与头孢菌素Ⅴ相同。对奇异变形杆菌CTM的活力最高,约4倍于CPZ;而CPZ
In this paper, we report two new cephalosporins: Cefoporazone (CPZ, T1551) and cefotiam (CTM, SCE963) and other clinically used cephalosporins In vitro antibacterial activity comparison. The test using agar plate dilution method, the test strains were used at a lower inoculum size (10 ~ 3 colony forming units, cfu / ml). The activity of CTM and CPZ against 24 strains of Escherichia coli was higher than that of Cefoxitin, Cefazolin and Cefuroxime. Among them, CTM activity was the highest. The tested strains of Klebsiella pneumoniae were all sensitive to CTM; however, only 20-25% of the strains were sensitive to CPZ at concentrations of 0.12-0.25 mg / l and the rest were inhibited at ≥4 mg / l. At this point The same as cephalosporin V. The highest activity of Proteus mirabilis CTM, about 4 times the CPZ; and CPZ